| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -13.9 | -10.1 |
| EPS (diluted, $ a share) | $-0.12 | $-0.30 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: RLMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Relmada Therapeutics, Inc.: key numbers
- Share price
- $3.61Close, Nov 16
- Market cap
- $385M
- Shares outstanding
- 106.69MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Relmada Therapeutics, Inc.
All →Relmada Therapeutics Leadership Change
Relmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology. Dr. Jakobsen previously led the global clinical development of ADSTILADRIN at Ferring Pharmaceuticals and will now lead Relmada's planned Phase 3 SPECTRUM registrational program for NDV-01 in bladder cancer.
Relmada Therapeutics Financial Results
Relmada Therapeutics reported third quarter 2026 financial results and provided a corporate update on its NDV-01 and sepranolone programs. The company ended the quarter with $202.1 million in cash, which is expected to fund operations through 2029, and remains on track to submit an IND for NDV-01 by year-end 2026.
“Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program.”
Sergio Traversa, Chief Executive Officer of Relmada Therapeutics
“Initial 18-month results from the ongoing NDV-01 Phase 2 study demonstrate extended durability of complete response and continued favorable tolerability. Our Phase 3 program remains unchanged, with two independent registrational pathways in NMIBC, and we have renamed it SPECTRUM to reflect the potential breadth of NDV-01 across the NMIBC disease spectrum. We expect to begin the SPECTRUM program upon IND clearance.”
Bipin Dalmia, Chief Business Officer of Relmada Therapeutics